$SNDX
Syndax Pharmaceuticals Inc

2018 Q3 Form 10-Q Financial Statement

#000156459018020483 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $379.0K $379.0K $305.0K
YoY Change 24.26% 24.26% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.130M $4.480M $4.290M
YoY Change 16.01% 4.43% 52.67%
% of Gross Profit
Research & Development $14.10M $14.85M $9.862M
YoY Change 15.65% 50.59% 60.85%
% of Gross Profit
Depreciation & Amortization $70.00K
YoY Change 600.0%
% of Gross Profit
Operating Expenses $18.22M $19.33M $14.15M
YoY Change 15.68% 36.64% 58.26%
Operating Profit -$17.84M -$18.95M -$13.84M
YoY Change 15.51% 36.91% 60.32%
Interest Expense $488.0K $459.0K $290.0K
YoY Change 18.73% 58.28% 5.07%
% of Operating Profit
Other Income/Expense, Net $503.0K $563.0K $203.0K
YoY Change 40.5% 177.34% -26.45%
Pretax Income -$17.34M -$18.39M -$13.64M
YoY Change 14.91% 34.82% 63.16%
Income Tax
% Of Pretax Income
Net Earnings -$17.34M -$18.39M -$13.64M
YoY Change 14.91% 34.82% 63.18%
Net Earnings / Revenue -4574.67% -4851.72% -4471.8%
Basic Earnings Per Share
Diluted Earnings Per Share -$680.8K -$744.2K -$699.5K
COMMON SHARES
Basic Shares Outstanding 23.36M 18.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.50M $99.80M $132.0M
YoY Change -24.69% -24.39% 4.85%
Cash & Equivalents $26.71M $32.20M $22.99M
Short-Term Investments $64.80M $67.60M $109.0M
Other Short-Term Assets $4.100M $4.600M $1.800M
YoY Change 115.79% 155.56% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $95.85M $104.7M $134.2M
YoY Change -22.69% -21.97% 5.33%
LONG-TERM ASSETS
Property, Plant & Equipment $396.0K $415.0K $260.0K
YoY Change 38.46% 59.62% -14.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $225.0K $259.0K $239.0K
YoY Change -4.66% 8.37% 38.15%
Total Long-Term Assets $621.0K $674.0K $499.0K
YoY Change 18.97% 35.07% 4.61%
TOTAL ASSETS
Total Short-Term Assets $95.85M $104.7M $134.2M
Total Long-Term Assets $621.0K $674.0K $499.0K
Total Assets $96.47M $105.4M $134.7M
YoY Change -22.51% -21.75% 5.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.180M $5.297M $3.362M
YoY Change 41.59% 57.56% 111.71%
Accrued Expenses $12.30M $12.50M $6.900M
YoY Change 14.95% 81.16% 86.49%
Deferred Revenue $1.517M $1.517M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.02M $19.30M $11.51M
YoY Change 19.77% 67.74% 75.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $148.0K $311.0K $214.0K
YoY Change -44.57% 45.33% -7.76%
Total Long-Term Liabilities $15.18M $15.72M $13.82M
YoY Change 11.83% 13.72% -8.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.02M $19.30M $11.51M
Total Long-Term Liabilities $15.18M $15.72M $13.82M
Total Liabilities $32.19M $35.02M $25.33M
YoY Change 15.89% 38.25% 17.18%
SHAREHOLDERS EQUITY
Retained Earnings -$420.6M -$403.2M -$331.9M
YoY Change 21.2% 21.49% 18.75%
Common Stock $2.000K $473.7M $441.2M
YoY Change -100.0% 7.36% 14.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.27M $70.35M $109.3M
YoY Change
Total Liabilities & Shareholders Equity $96.47M $105.4M $134.7M
YoY Change -22.51% -21.75% 5.33%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$17.34M -$18.39M -$13.64M
YoY Change 14.91% 34.82% 63.18%
Depreciation, Depletion And Amortization $70.00K
YoY Change 600.0%
Cash From Operating Activities -$18.47M -$15.15M -$11.80M
YoY Change 81.43% 28.39% 71.26%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $3.510M $19.28M -$36.60M
YoY Change -49.57% -152.68% 6435.71%
Cash From Investing Activities $3.510M $19.29M -$36.60M
YoY Change -49.28% -152.7% 5803.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.460M 90.00K 48.98M
YoY Change 836.63% -99.82% -4082.11%
NET CHANGE
Cash From Operating Activities -18.47M -15.15M -11.80M
Cash From Investing Activities 3.510M 19.29M -36.60M
Cash From Financing Activities 9.460M 90.00K 48.98M
Net Change In Cash -5.500M 4.230M 580.0K
YoY Change 144.44% 629.31% -106.64%
FREE CASH FLOW
Cash From Operating Activities -$18.47M -$15.15M -$11.80M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$18.47M -$15.15M -$11.80M
YoY Change 82.15% 28.39% 73.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Central Index Key
EntityCentralIndexKey
0001395937
dei Entity Registrant Name
EntityRegistrantName
SYNDAX PHARMACEUTICALS INC
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-11
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23355013
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32204000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35168000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
101000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
106000
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
66181000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
94806000
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6210000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3362000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
104696000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
133442000
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
3246000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
415000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
267000
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
259000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2018Q2 us-gaap Assets
Assets
105370000
CY2017Q4 us-gaap Assets
Assets
137186000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5297000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2232000
CY2018Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12484000
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11993000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19298000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15798000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
311000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
310000
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
15720000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
17069000
CY2018Q2 us-gaap Liabilities
Liabilities
35018000
dei Trading Symbol
TradingSymbol
SNDX
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3067000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
800000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-758000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
451000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35019000
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
94000
CY2018Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
252000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
258000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2825000
CY2018Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1517000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1573000
CY2018Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
15409000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16759000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q4 us-gaap Liabilities
Liabilities
32867000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
473686000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
470571000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-89000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-143000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-403247000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-366111000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
70352000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
104319000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105370000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9270000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
14147000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18951000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
104000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
917000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137186000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22705794
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24390033
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22705794
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24390033
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
379000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
305000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
758000
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2017Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-13639000
us-gaap Net Income Loss
NetIncomeLoss
-37785000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
129000
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
54000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18259000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13601000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18388000
us-gaap Operating Expenses
OperatingExpenses
39460000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13842000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38702000
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
459000
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
290000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
934000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24592483
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24705441
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19497581
us-gaap Profit Loss
ProfitLoss
-37785000
us-gaap Profit Loss
ProfitLoss
-26610000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-137000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
79000
us-gaap Share Based Compensation
ShareBasedCompensation
2992000
us-gaap Share Based Compensation
ShareBasedCompensation
2825000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2847000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1082000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-610000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
122000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24468000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
173000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
34149000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
87989000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
66250000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
62447000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31928000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25542000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48836000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
269000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
97000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
122000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49104000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2969000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-906000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24110000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32420000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23204000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
41000
sndx Issuance Costs Included In Accounts Payable And Accrued Expenses
IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
32000
sndx Issuance Costs Included In Accounts Payable And Accrued Expenses
IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
161000
sndx Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
59000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syndax Pharmaceuticals, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in Delaware in 2005. We base our operations in Waltham, Massachusetts and we operate in one segment.</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:bold;"> </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. </p></div>
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
216000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
221000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71016000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
108391000
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
143000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
70927000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
108248000
CY2018Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1405000
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1286000
CY2018Q2 us-gaap Supplies
Supplies
2194000
CY2017Q4 us-gaap Supplies
Supplies
220000
CY2017Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
377000
CY2018Q2 sndx Reimbursable Costs
ReimbursableCosts
1635000
CY2017Q4 sndx Reimbursable Costs
ReimbursableCosts
1029000
CY2018Q2 us-gaap Prepaid Insurance
PrepaidInsurance
439000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
192000
CY2018Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
285000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
776000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
265000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1794000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2393000
CY2018Q2 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
9749000
CY2017Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
9177000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
165000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
158000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1570000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1448000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2992000
CY2018Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7850
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7850
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
91000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2992000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
97000
sndx Cumulative Effects Adjustment From Adoption Of New Accounting Standard
CumulativeEffectsAdjustmentFromAdoptionOfNewAccountingStandard
649000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
16780000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16780000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
sndx Tax Cuts And Jobs Act Of2017 Accounting Complete
TaxCutsAndJobsActOf2017AccountingComplete
true
CY2017Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2017Q4 sndx Tax Cuts And Jobs Act Transition Tax For Accumulated Foreign Earnings Liability
TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiability
0

Files In Submission

Name View Source Status
0001564590-18-020483-index-headers.html Edgar Link pending
0001564590-18-020483-index.html Edgar Link pending
0001564590-18-020483.txt Edgar Link pending
0001564590-18-020483-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-10q_20180630.htm Edgar Link pending
sndx-20180630.xml Edgar Link completed
sndx-20180630.xsd Edgar Link pending
sndx-20180630_cal.xml Edgar Link unprocessable
sndx-20180630_def.xml Edgar Link unprocessable
sndx-20180630_lab.xml Edgar Link unprocessable
sndx-20180630_pre.xml Edgar Link unprocessable
sndx-ex101_116.htm Edgar Link pending
sndx-ex311_6.htm Edgar Link pending
sndx-ex312_9.htm Edgar Link pending
sndx-ex321_7.htm Edgar Link pending